Neurosense Therapeutics Ltd. · NASDAQ:NRSN
Neurosense Therapeutics — Investor Presentation (July 2026)
32 slides from Neurosense Therapeutics's investor presentation, July 2026
Slide 1: Corporate Presentation
Corporate Presentation July 2026 Nasdaq: NRSN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and oral statements made regarding this presentation contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this pr
Slide 3: NeuroSense Therapeutics
NeuroSense Therapeutics Clinical-stage biotech developing novel therapies for neurodegenerative diseases of a high unmet need A Phase 3-ready asset, PrimeC is being developed for treatment of ALS ALS - Amyotrophic Lateral Sclerosis 3
Slide 4: NeuroSense Highlights
NeuroSense Highlights Primary endpoint met: PrimeC slowed Unprecedented Patent coverage for Clear regulatory significant reduction in disease progression median survival novel formulation, pathway difference of method & TDP-43 by ~ 33% combination Phase 3 ready (p=0.04), a central (p=0.007) over 18
Slide 5: ALS is a Terminal Disease with a Huge Unmet Need and Few Treatment Options
ALS is a Terminal Disease with a Huge Unmet Need and Few Treatment Options Rapidly progressing with a median survival of 3 years1 o Caused by death of motor neurons o Muscle weakness and paralysis leading to inability to speak and move, respiratory failure and death o 5-10% of cases are genetic Dec.
Slide 6: PrimeC: A Promising Commercial Opportunity in ALS Treatment
PrimeC: A Promising Commercial Opportunity in ALS Treatment >80,000 >$1B ALS patients in NeuroSense’s Annual Market Opportunity2 planned target market1 ~$150,000/year ~24% The price of ALS drugs (Radicava ORS) 3 Growth in patients by 2040 in the US and EU1 >30,000 People in the US are currently livi
Slide 7: PrimeC: Rational Combination Therapy
PrimeC : Rational Combination Therapy • Novel Formulation: Fixed- dose combination of 2 approved drugs • Extended-Release: Unique formulation synchronizes the pharmacokinetics (PK) profiles of both drugs despite their distinct physicochemical and pharmacokinetic properties • Multi- Targeted Action:
Slide 8: PrimeC Targets Multiple Key Pathways in ALS
PrimeC Targets Multiple Key Pathways in ALS Neuroinflammation Iron Metabolism Dysregulation miRNA Dysregulation o A COX-2 inhibitor and anti-inflammatory drug o An iron chelator o Enhancer of miRNA modulation o Neuroinflammation is a key driver of disease o Iron dysregulation promotes oxidative o Mi
Slide 9: Non-Clinical & Early Clinical Studies
PrimeC Rationale Demonstrated in Non-Clinical and Clinical settings Reduced Neuroinflammation and TDP-43 Levels in ALS Patients Superior Neuronal Survival in human iPSC C9orf72 ALS Model ALS (Phase 2a) patient blood Non- Clinical & Early Clinical Studies Differentiation Reprogramming ALS Therapeutic
Slide 10: PARADIGM Phase 2b Trial
PARADIGM Phase 2b Trial o A randomized (2:1), placebo-controlled, double-blind, multi-center trial (NCT05357950), followed by an open-label extension o Enrolled ALS patients with disease duration of <30 months and upright slow vital capacity (SVC) ≥ 60% o Standard of care (SOC) allowed and balanced
Slide 11: Well-balanced at baseline across key prognostic variables
Well-balanced at baseline across key prognostic variables Baseline Demographic & PrimeC Placebo Disease Characteristics n=45 n=23 TRICALS Risk Profile -4.2 -4.4 Phase 2b ALSFRS-R 37.5 37.5 BMI (kg/m2) 24.1 24.0 Months from symptom onset 16.7 15.1 Male 60.0% 60.9% Female 40.0% 39.1% Age 59.1 54.9 Pat
Slide 12: PrimeC Demonstrated Safety & Tolerability Throughout PARADIGM
PrimeC Demonstrated Safety & Tolerability Throughout the Entire Duration of PARADIGM, Achieving Primary End Point Double-Blind Open-Label Extension 6 Months 12 Months Phase 2b o The study demonstrated a favorable safety and tolerability profile o 18-month study data confirmed no differences in treat
Slide 13: New Data: Primary Endpoint TDP-43
New Data: Primary Endpoint TDP-43 MoA Rifai et al. 2026; Iguchi et al. 2016; Chatterjee et al. 2024; Feneberg et al. 2014; Walker et al. 2013; Suk and Rousseaux 2020; Zuo et al. 2021; Balendra et al. 2025; Jinno et al. 2025; Bose et al. 2011; Swarup et al. 2011; Cohen et al. 2012; Chou et al. 2018;
Slide 14: Primary Endpoint Met - PrimeC Significantly Reduced TDP-43 Levels After 6 Months
New Data: Primary Endpoint Met - PrimeC Significantly Reduced TDP-43 Levels After 6 Months of Treatment At Day 180, a statistically significant reduction in TDP-43 levels was observed in the PrimeC group compared to placebo (LS mean difference −0.22; 95% CI −0.43 to −0.01; p=0.042), demonstrating a
Slide 15: PrimeC Produced a Sustained, Statistically Significant Reduction in TDP-43 levels
New Data: PrimeC Produced a Sustained, Statistically Significant Reduction in TDP-43 levels Phase 2b p value 0.96 0.02 0.04 0.004 <0.001 <0.001 <0.001 Placebo N 22 22 22 19 17 10 9 7 PrimeC N 45 43 40 38 31 29 22 20 Adjusted mean score, the treatment difference and p-value are analyzed using MMRM *
Slide 16: PrimeC Slowed Disease Progression by 29.2% After 6 Months of Treatment
PrimeC Slowed Disease Progression by 29.2% After 6 Months of Treatment (Double-Blind Period) Double-Blind Period ALSFRS-R Total Score 40 (6 Months) 0 Placebo Mean ALSFRS-R Score PrimeC -1 PrimeC * 40.1% Placebo -2 Number of Points Lost 35 p = 0.05 -5.41 -3 -7.64 Phase 2b -4 -5 29.2% 30 p = 0.12 -6 -
Slide 17: Early Treatment with PrimeC Led to Better Clinical Outcomes
Early Treatment with PrimeC Led to Better Clinical Outcomes Open-Label Extension Double-Blind (12 Months) (6 Months) 48 Placebo to ALSFRS-R Total Score Mean PrimeC Sub-Domain PrimeC Mean Difference PrimeC 40 Placebo 29.2% * 36.5% p = 0.12 p = 0.008 Placebo to PrimeC ** 30 7.8 4.7 3.2 ** Bulbar * **
Slide 18: PrimeC Treatment Reduced Likelihood of Mortality, Hospitalization, and Respiratory Support
PrimeC Treatment Reduced Likelihood of Mortality, Hospitalization, and Respiratory Support o 18-month PrimeC treatment resulted in a Double-Blind Open-Label Extension better survival outcome, with a 58% 6 Months 12 Months improvement in survival rates Summary of secondary and DB DB + OLE o Participa
Slide 19: ~15-Month Survival Advantage: Unprecedented in ALS
~15-Month Survival Advantage: Unprecedented in ALS Kaplan-Meier Survival Analysis Additional long-term follow-up of up to 36 months; Survival was calculated from the date of randomization to the date of death ▪ PrimeC (n=45): 36.3 months Phase 2b ▪ Placebo (n=23): 21.4 months o Long-term survival wi
Slide 20: Correlations with PARADIGM Biomarker Results
PARADIGM Biomarker Results Regulation of Key miRNAs Related to ALS Progression Iron Target Engagement Ferritin Transferrin Open-Label Entire Study Period (18 Months) Open-Label Extension Extension PrimeC Double-Blind Double-Blind (12 Months) PrimeC (12 Months) (6 Months) (6 Months) Placebo to PrimeC
Slide 21: References
Cudkowicz et al. 2026; Salomon-Zimri et al. 2023; Shishodia et al. 2004; Gong et al. 2012; Al-Rashed et al. 2018; Swarup et al. 2011; Correia et al. 2015; Bose et al. 2011, Huang et al. 2020; Elmi et al. 2009; Zusso et al. 2019; Jinno et al. 2025; Cohen et al. 2012 21
Slide 22: PrimeC: Converging Evidence Supports Disease Modification
PrimeC: Converging Evidence Supports Disease Modification o Strong safety and tolerability profile o Functional → 32.8% slowing (ALSFRS-R, p=0.007) after 18 months in patients treated with PrimeC compared to those initially on placebo o Survival → 15-month median difference (p=0.02); 65% improvement
Slide 23: Phase 3
Double-Blind – 48 weeks Open-Label Extension – 48 weeks PrimeC (N=200) PrimeC Placebo (N=100) Phase 3 A Phase 3, Randomized, Multi-center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, with an Open Label Extension, to Evaluate Safety and Efficacy of PrimeC in participants livin
Slide 24: Study End Points
Study End Points Primary Efficacy End Points: • The mean change in ALSFRS-R total score progression rate over 48 weeks, adjusted for mortality* Key Secondary End points • Time to MiToS stage progression or death (48 weeks) • Overall survival composite: death, respiratory insufficiency (≥22 h/day for
Slide 25: Study Aims and Study Sites
Study Aims Study Sites Objective: To evaluate the safety, tolerability, and efficacy of PrimeC compared to placebo in individuals with ALS. A global geographic distribution of participants, mainly from the United States. Methods: PARAGON is a 48-week, Phase 3, randomized, multinational, multi-center
Slide 26: Enrollment Criteria
Enrollment Criteria Inclusion Criteria • Age 18–75 years (male or female) with probable or definite ALS per revised El Escorial criteria • TRICALS risk score –2 to –6 at screening Phase 3 • Disease duration ≤18 months from first symptom • Pre-enrollment ALSFRS-R slope ≥0.3 points/month • ALSFRS-R to
Slide 27: Phase 3 Planned Study Timelines
Planned Study Timelines* H2 2026 H2 2027 H2 2028 Begin Enrollment First Patient Out Last Patient Out Phase 3 • The clinical and biomarker findings from PARADIGM provide a strong rationale for advancing PrimeC into the planned PARAGON Phase 3 trial. • PARAGON’s adaptive design and comprehensive endpo
Slide 28: PrimeC- A Phase 3-Ready Potential Disease-Modifying Therapy for ALS
PrimeC- A Phase 3-Ready Potential Disease-Modifying Therapy for ALS o Compelling and consistent data from a Phase 2b study, demonstrating a 32.8% slowing in disease progression over 18 months (p=0.007) and ~ 15 months median survival difference compared to patients initially on placebo o Strong biom
Slide 29: Exceptional Scientific Advisory Board
Exceptional Scientific Advisory Board Prof. Jeremy Shefner Prof. Orla Hardiman Prof. Merit Cudkowicz Prof. Jinsy Andrews Prof. Jeffrey Rosenfeld Dr. Steven E. Arnold (Chair) Professor of Neurology, Senior Vice President Head of Academic Unit of Executive Director, Mass General Professor of Neurology
Slide 30: Leadership
Leadership Alon Ben-Noon Niva Russek-Blum, PhD Or Eisenberg Hagit Binder Ferenc Tracik, MD Shiran Zimri, PhD Founder & CEO Chief Technology Officer Chief Financial Officer General Manager Former Chief Medical Officer; VP R&D / Country Lead, Canada & Chief Operating Officer Clinical Advisor 30
Slide 31: Thank You
Thank You "I may be paralyzed, but I can move mountains” - Shay Rishoni We thank the trial participants along with their families and caregivers, for choosing to participate in this study We extend our heartfelt gratitude to all the clinical sites (Prof. Drory, Dr. Lunetta, Prof.Chio, Dr. Shoesmith)
Slide 32: Nasdaq: NRSN
Nasdaq: NRSN For more information: info@neurosense-tx.com
NeuroSense Therapeutics — Investor Presentation (July 2026) on 6ix